Illumina (NASDAQ:ILMN) updated its FY 2019 earnings guidance on Monday. The company provided EPS guidance of $6.00-6.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.38. The company issued revenue guidance of $3.53298-3.53298 billion, compared to the consensus revenue estimate of $3.62 billion.Illumina also updated its FY19 guidance to $6.00 to $6.10 EPS.
Several research firms have weighed in on ILMN. OTR Global cut Illumina to a positive rating in a research report on Tuesday, April 2nd. Zacks Investment Research cut GasLog Partners LP Unit from a hold rating to a strong sell rating in a research report on Tuesday, April 2nd. Wolfe Research began coverage on Waters in a research report on Thursday, May 30th. They issued an underperform rating on the stock. UBS Group cut their price objective on Texas Roadhouse from $65.00 to $62.00 and set a neutral rating on the stock in a research report on Tuesday. Finally, Piper Jaffray Companies cut their price objective on Illumina from $382.00 to $348.00 and set an overweight rating on the stock in a research report on Tuesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $332.77.
NASDAQ ILMN traded up $2.70 during trading on Wednesday, reaching $302.66. The company’s stock had a trading volume of 32,294 shares, compared to its average volume of 1,559,709. The company has a market capitalization of $43.87 billion, a PE ratio of 52.96, a PEG ratio of 2.62 and a beta of 1.15. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.33. The stock has a fifty day moving average of $337.89. Illumina has a one year low of $268.62 and a one year high of $380.76.
In other news, Director Jay T. Flatley sold 3,300 shares of the stock in a transaction dated Wednesday, May 8th. The stock was sold at an average price of $318.59, for a total transaction of $1,051,347.00. Following the transaction, the director now directly owns 285,816 shares in the company, valued at approximately $91,058,119.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Omead Ostadan sold 1,260 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $315.32, for a total value of $397,303.20. The disclosure for this sale can be found here. Insiders have sold a total of 61,167 shares of company stock worth $19,899,477 over the last quarter. Corporate insiders own 0.38% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: Gap Up Stocks
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.